Kornimate/medical-research-clean huggingface dataset:
obstacle negotiation in older people with and without vision impairment

Conditions: Low Vision

Summary: falls are common among people with vision impairment and can lead to devastating health consequences. understanding the functions of vision and how the visual characteristics of obstacles in the walking path impact the gait of people with vision impairment is necessary to create strategies to prevent falls in this population. the purpose of this study is to determine how adults with vision impairment change their gait behavior when stepping over obstacles that vary in height and contrast to the ground. we will then determine the mechanisms of gaze behavior that correlate to the gait behavior.


Eligibility criteria:
inclusion criteria: * age 18 or over * able to walk independently * either have normal vision, or impaired vision. * impaired vision is defined as binocular visual acuity of 20/25 or worse with or without a central scotoma; and/or binocular visual field that is restricted to an average of 100 degrees in diameter or less * control subjects will have visual acuity of 20/40 or better. exclusion criteria: * not cleared by a medical provider for moderate physical activity * self-report or have a history of: vestibular disorder or deafness * medical history of any condition that affects the ability to walk for up to 2 hours with breaks, such as feeling dizzy or faint, chest pain, palpitations, pain or numbness in the legs, shortness of breath, * cognitive limitations either by self-report or a score on the mini mental state exam below 24 (out of 30) * walking or gait abnormalities, such as those caused from an injury, surgery, severe arthritis, or neurological condition such as parkinson's disease * unable to walk without any walking aids such as a walker, cane, guide dog, or oxygen tank. * does not speak english
european survey of non-variceal upper gastro intestinal bleeding (nvugib)

Conditions: Non-variceal Upper Gastrointestinal Bleeding; Gastrointestinal Ulcer; Gastrointestinal Hemorrhage

Summary: the aim of this study is to assess the current management strategies in a pan-european "real-life" setting to uncover the unmet need in this area: non-variceal gastrointestinal bleedings.


Eligibility criteria:
inclusion criteria: * patients admitted to the hospital or inpatients with an overt non-variceal upper gi bleed manifesting as hematemesis/coffee ground vomiting, melena, hematochezia, as well as other clinical/laboratory evidences of acute blood loss from the upper gi tract * evidence that an upper gi endoscopy was performed * the complete medical record is available for study related hospitalization. exclusion criteria: * na

Keywords: bleeding ulcer hemorrhage gastrointestinal diseases digestive system disease peptic ulcer proton pump inhibitor
role of residual urine and asymptomatic prostatitis in the development of urinary tract infections in spinal cord injury

Conditions: Urinary Tract Infection

Summary: the purpose of this prospective study is to investigate the association between the amount of residual urine and asymptomatic bacterial prostate infection with the occurrence of recurrent (\>2 /year) symptomatic urinary tract infections in patients suffering from chronic (\> 1 year) spinal cord injury (sci) and neurogenic lower urinary tract dysfunction performing intermittent catheterization. the following hypotheses will be tested: 1. the amount of residual urine after intermittent catheterization is significantly greater in sci patients suffering from frequent (\>2 /year) urinary tract infections compared to those without. 2. the incidence of asymptomatic bacterial prostate infections is significantly higher in sci patients suffering from frequent (\>2 /year) urinary tract infections compared to those without.

to investigate the association between the amount of residual urine and asymptomatic bacterial prostate infection with the occurrence of recurrent (\>2 /year) symptomatic urinary tract infections in patients suffering from chronic (\> 1 year) spinal cord injury (sci) and neurogenic lower urinary tract dysfunction performing intermittent catheterization, patients perform self-catheterization twice (before and after urodynamic testing. after each catheterization, residual urine is assessed by ultrasound. prior to urodynamic testing, prostate massage is performed, bacterial cultures of the fluid and the urine are initiated and the results of these cultures will be analysed .

Eligibility criteria:
inclusion criteria: * male patients with chronic (\> 1 year) spinal cord injury * bladder management by intermittent catheterization exclusion criteria: * symptomatic urinary tract infection * prostate pathology * immunodeficiency * antibiotic therapy * missing informed consent

Keywords: urinary tract infection bacteriuria pyuria prostatitis intermittent catheterization spinal cord injuries residual urine
exercise duration models, in middle-aged men

Conditions: Weight Loss

Summary: duration of exercise is an important factor among the medical guides for weight loss. however, there is still little knowledge about other its models in middle-aged and older men. the present study aimed to determine the effects of the interval training on weight loss and lipid profile, and to compare its efficiency with the continuous training.

participants included sedentary men (age 45-75 years) with overweight or obesity (n= 82). they were randomly divided into two groups including continuous exercise, and interval exercise. the weight assessment parameters including change in weight and body composition, blood sample tests were performed pre- and three month post-intervention.

Eligibility criteria:
inclusion criteria: * sedentary lifestyle * good health * weight stability exclusion criteria: abnormality or history of disease

Keywords: caloric restriction dietary formulations exercise men
validation of a rapid, non-invasive point-of-care ivd test for diagnosis of sars-cov-2 (covid-19) infection

Conditions: SARS-CoV

Summary: a prospective non-interventional study to evaluate the performance of easycov ivd as point-of-care (poc) test by comparing sars-cov-2 positive patients with sars-cov-2 negative controls on paired specimens (nasopharyngeal swabs \& saliva samples).

a prospective non-interventional study to evaluate the performance of easycov ivd as point-of-care (poc) test by comparing sars-cov-2 positive patients with sars-cov-2 negative controls on paired specimens (nasopharyngeal swabs \& saliva samples). the operators performing the diagnostic tests will be blinded from the rt-pcr results (i.e. participant's group will be anonymized). participants who have been tested by an routineturkish moh and fda eua approved rt-pcr test using nasopharyngeal swabs will be included in the study to perform the easycov ivd tests in a poc setting. primary objective: • to evaluate the performance of easycov ivd as a point-of-care (poc) test performed on saliva samples for the diagnosis of sars-cov-2 infection by comparing it to a turkish moh and fda eua approved rt-pcr test performed on nasopharyngeal samples. secondary objectives: • collection and storage of saliva samples, nasopharyngeal swabs at d0 to perform future covid-19 related research projects and validation of future generations of easycov assays as well as exploratory studies to find candidate biomarkers for covid-19. 160 participants will be included in 1:1 ratio: 80 sars-cov-2 positive and 80 sars-cov-2 negative by a turkish moh and fda approved rt-pcr ivd test

Eligibility criteria:
inclusion criteria: non-specific inclusion criteria: 1. participant aged 18 and above 2. participant agreeing to follow the study procedures 3. participant able to understand the purpose, nature and methodology of the study 4. participant having signed the informed consent specific inclusion criteria: sars-cov-2 positive patients - participants tested positive for the sars-cov-2 by the routine turkish moh and fda approved rt-pcr method. sars-cov-2 negative controls - participants tested negative for the sars-cov-2 by the routine turkish moh and fda approved rt-pcr method. exclusion criteria: * minors, persons deprived of their liberty, protected adults or vulnerable persons. * refusal to sign the consent.

Keywords: sars coronavirus coronavirus covid-19
health impact of l.reuteri consumption in crew members of a naval ship at sea

Conditions: Gingivitis

Summary: this study is designed to evaluate the impact of the regular consumption of probiotic lactobacillus reuteri-containing lozenges over a period of 42 days on parameters of oral and general health in crew members of a naval ship at sea.

probiotic strains of lactobacillus reuteri have demonstrated a significant impact on the composition of the oral and intestinal microbiome as well as modulating the host response in several clinical trials and in vitro experiments. this two-arm double blind placebo controlled clinical trial will evaluate the impact of the regular consumption of l.reuteri-containing lozenges over a period of 42 days on parameters of oral and general health in crew members of a naval ship at sea. 2 x 36 healthy study subjects will be recruited from the crew members of the ship. at baseline and at the end of the study (day 42) the following parameters will be recorded at the ramfjord teeth (teeth 16, 21, 24, 36, 41, 44): bleeding on probing (bop) as the primary outcome secondary outcomes will be gingival index (gi) plaque control record (pcr) pocket probing depth (ppd) pooled oral and intestinal (stool) microbial samples will be taken at baseline and at the end of the study for the subsequent analysis of the * composition of the oral microbiome * composition of the intestinal microbiome by whole genome sequencing furthermore the frequency of short-term sick leave due to respiratory or intestinal diseases among the study participants during the observation period will be recorded.

Eligibility criteria:
inclusion criteria: minimum of 12 natural teeth exclusion criteria: regular intake of antiinflammatory drugs affecting periodontal health (e.g. nsaids) manifestation of systemic disease affecting periodontal health (e.g. diabetes) use of antiseptic oral mouthrinses drug/alcohol abuse
alln-346 single ascending dose (sad) study in healthy volunteers

Conditions: Hyperuricemia

Summary: the purpose of this study is to evaluate the safety of alln-346 in healthy volunteers, in this first in human, single ascending dose study. alln-346 is an enzyme that degrades urate in the gastrointestinal tract.

this is a phase i, randomized, double-blind, placebo-controlled single ascending dose study of orally administered alln-346. the study will evaluate the safety and tolerability, inflammation and immunogenicity, pharmacokinetics and pharmacodynamics of alln-346 in healthy volunteers. the study consists of a screening period, a treatment period of 3 days, which includes 1 single day of dosing and 3 days of in-house observation, and a safety follow-up period through day 28 following dosing.

Eligibility criteria:
inclusion criteria: * signed informed consent form * incapable of pregnancy, not nursing, and agrees to use an effective method of contraception; males subjects must agree to abstain from sperm donation * good general health as determined by medical history and physical examination * normal clinical laboratory test results and ecg exclusion criteria: * presence or history of any significant cardiovascular, gastrointestinal, hepatic, renal, pulmonary, hematologic, endocrine, immunologic, dermatologic, neurological, psychiatric disease or history of hyperuricemia * any other condition (including surgery) known to interfere with the absorption, distribution, metabolism, or excretion of medicines * positive screen results for drugs of abuse, alcohol, or cotinine or recent history of drug or alcohol abuse * clinically significant abnormal findings on physical examination, vital signs or on electrocardiogram (ecg) * positive test result for hepatitis b surface antigen, hepatitis c virus antibody, or human immunodeficiency virus (hiv) antibody * received treatment with or exposure to an investigational drug or device within 30 days prior to or during screening * per investigator judgment, is not an ideal clinical study candidate

Keywords: hyperuricemia gout urate oxidase uric acid
novel one-step repair of knee meniscal tear using platelet-rich fibrin

Conditions: Meniscal Injuries

Summary: currently, most knee meniscal tears are treated by partial or complete meniscectomy, or by suture repair when it is possible. recently, the investigators have successfully developed and implanted a novel biomaterial, platelet-rich fibrin (prf), to treat articular cartilage defect in pigs. the prf is autogenesis as a natural fibrin-based biomaterial favorable to the development of microvascularization and enables local and progressive delivery of growth factors providing unique properties for tissue remodeling and wound healing. the advantages of using prf implantation include no transplant rejection and no need to perform second operation. knee meniscal repair using prf has not been reported before. the aim of this study is to investigate whether prf implantation can facilitate regeneration process of meniscectomized knee and t2-map mri can monitor the process in those patients with meniscal tears. a total of 18 adult patients with torn menisci (outer 1/3, posterior horn, medial meniscus) will be recruited and randomly divided into three groups: a (n=6), implantation of prf after partial menisectomy; b (n=6), implantation of prf after partial menisectomy and suture; c (n=6), partial menisectomy only. all studied knee will be scanned on a 1.5-t mri with surface coil at baseline before surgery, 3 months and 6 months and 12 months after surgery. the investigators believe that prf enables to facilitate regeneration of meniscectomized knee, and t2-map mri enables monitoring healing process of meniscal tears.


Eligibility criteria:
inclusion criteria: * 20 to 45 years old; * time of injury to surgery within 8 weeks * patients who will sign inform consent * patients with clinical and mri diagnosis of meniscal tears who will undergo arthroscopy * patients who will make mri diagnosis at 3, 6, 12 months exclusion criteria: * major trauma * coexist ligamentous rupture * knee dislocations
outcome prediction in patients with acute disorders of consciousness

Conditions: Consciousness Disorder

Summary: prior research has indicated a link between outcomes in patients with disorders of consciousness (doc) and their responses to emotional auditory stimuli. given the high degree of uncertainty in acute situations, this study plans to record eeg responses and observe microexpressions in doc patients during exposure to auditory stimuli, with the aim to identify more reliable prognostic indicators. the goal is to uncover potential patterns or signals that can contribute to a more comprehensive understanding of a patient's condition, and thereby provide more accurate prognostication.

this study intends to probe the potential of electroencephalography (eeg) and microexpression analysis for predicting the outcomes of acutely unresponsive patients within the intensive care unit (icu). previous research has illuminated a relationship between patients' emotional responses to auditory stimuli and their prognosis. however, the predictive utility of these responses in the context of acute conditions remains largely unexplored. at the onset of the study, participants will undergo eeg monitoring while exposed to a pre-determined set of emotional auditory stimuli. additionally, the patients' facial expressions will be captured via video for subsequent microexpression analysis. follow-up assessments of the patients' status will be conducted at three, six, and twelve-month intervals. using cutting-edge analytical techniques, the goal is to decode these eeg and microexpression responses. this study aims to identify possible correlations between these findings, the patients' diagnoses, and their respective outcomes over time.

Eligibility criteria:
inclusion criteria: * patients with acute brain injury (\<28 days) in icu * gcs ≤ 8 * ≥ 2 days after sedation * normal hearing, with auditory startle reflex exclusion criteria: • children under 18
application of a novel biomarker based on plasma cfdna assay in the early diagnosis of prostate cancer

Conditions: Prostate Cancer

Summary: the goal of this diagnostic test is to obtain multiple cell-free dna （cfdna） fragment profiles of subjects by whole genome sequencing based on plasma cfdna, build a prostate cancer prediction model by machine learning, and to validate the efficacy of this model in patients who need to undergo needle prostate biopsy base on their prostate-specific antigen（psa） or clinical or imaging evidence. therefore, this study aims to explore the efficacy of this prostate cancer prediction model in distinguishing between patients with psa "gray zone" (4-10 ng/ml) in the diagnosis of prostate cancer and patients with clinically significant prostate cancer.


Eligibility criteria:
inclusion criteria: 1. male, 18-80 years old; 2. psa: 4-10ng/ml; 3. patients scheduled for prostate biopsy： * fpsa（free psa）/psa \ 0.15 (ng/ml/cm³) or psav（psa velocity） \> 0.75 (ng/ml/year) ② positive dre （digital rectal examination） ③suspicious positive lesions on ultrasound/mri). exclusion criteria: 1. patients with a prior diagnosis of any malignancy within 5 years; 2. patients who have undergone prior transurethral resection or enucleation of the prostate; 3. patients who have received prior treatment for prostate cancer, including but not limited to endocrine therapy, targeted therapy, and immunotherapy; 4. patients with long-term use of anticoagulant and antiplatelet aggregation drugs (anticoagulant discontinued for less than 1 week); 5. received any form of oncological treatment, including surgery, radiotherapy/chemotherapy, endocrine therapy, targeted therapy, and immunotherapy prior to enrollment for blood sampling; 6. concurrently suffering from other serious systemic diseases that, in the opinion of the investigator, may interfere with the treatment, evaluation and compliance of this trial, including serious respiratory, circulatory, neurological, psychiatric, gastrointestinal, endocrine, immune, urinary and other systemic diseases; 7. organ transplant recipients or prior non-autologous (allogeneic) bone marrow or stem cell transplant population; 8. subjects who have had a blood transfusion 1 month prior to the blood draw; 9. patients who are participating in other clinical trials, or who have participated in other clinical trials that have been completed less than 1 year ago; 10. patients who, in the judgment of the investigator, are not suitable for participation in this clinical trial; 11. patients who meet any of the above criteria may not be included as subjects.

Keywords: elevated psa biopsy prostate cancer prostate neoplasms cfdna machine learning
proteomic assessment of preterm birth

Conditions: Preterm Birth

Summary: the purpose of this study is to to collect and store blood samples that will be utilized to develop a multimarker test to predict preterm delivery.


Eligibility criteria:
inclusion criteria: * subject is 18 years or older. * subject has a singleton pregnancy. * subject is able to provide consent. exclusion criteria: * subject is pregnant with more than one fetus. * there is a known or suspected fetal anomaly.

Keywords: preterm birth, proteomics
rt-310 dose escalation bph study

Conditions: BPH (Benign Prostatic Hyperplasia); Lower Urinary Tract Symptoms

Summary: rt-310, a novel implant, is intended to minimally invasive treat locally the prostate gland for the management of prostate disease, while minimizing side-effects. the objectives of the study are to assess whether rt-310 is safe and feasible for the participant population.

the rt-310 study is a first in human phase 1 multi-center prospective, non-randomized dose escalation study to evaluate the safety and feasibility of rt-310 for treatment of benign prostatic hyperplasia (bph). study participants will have placement of rt-310 and be followed through 180 days.

Eligibility criteria:
key inclusion criteria: * male gender * diagnosis of symptomatic bph * age ≥ 50 years up to 80 years * international prostate symptom score (ipss) ≥ 13 * prostate volume 30 to 80 cc per ultrasound * inadequate response and/or refusal of medical therapy for luts key exclusion criteria: * current urinary retention or at significant risk of urinary retention after drug washout * have an obstructive or protruding median lobe of the prostate * previous bph surgical procedure or implants, urethral stricture, any prior minimally invasive intervention (e.g. tuna, balloon, microwave, rezūm, urolift) or surgical intervention of the prostate * previous pelvic surgery or irradiation * history of neurogenic or atonic bladder * stress urinary incontinence, mixed or urge incontinence * history of prostate or bladder cancer, confirmed or suspected malignancy of prostate or bladder * history of compromised renal function or upper urinary tract disease * other co-morbidities that could impact the study results such as: severe cardiac arrhythmias uncontrolled by medications or pacemaker; congestive heart failure new york heart association (nyha) iii or iv; history of uncontrolled diabetes mellitus; significant respiratory disease in which hospitalization may be required * known immunosuppression (i.e. aids, post-transplant, undergoing chemotherapy) * no more than two documented active urinary tract infections (uti) by culture or bacterial prostatitis within last year documented by culture (uti is defined as \>100,000 colonies per ml urine from midstream clean catch or catheterization specimen) * current gross hematuria and/or visible hematuria with participant urine sample without known contributing factor * presence of a penile implant or stent(s) in the urethra or prostate * psa \> 10 ng/ml unless prostate cancer is ruled out by biopsy. if psa is \> 4 ng/ml and ≤ 10 ng/ml, prostate cancer must be ruled out to the satisfaction of the investigator via additional tests including digital rectal exam (dre) and/or biopsy * sensitivity to rt-310 * unable to undergo magnetic resonance imaging (mri) such as presence of cardiac pacemaker or implanted cardiac defibrillator * parkinson's disease or other neurologic disease that may impact bladder function such as stroke, tia, multiple sclerosis
[18f]iso-1 positron emission tomography (pet/ct) in primary breast cancer

Conditions: Breast Cancer; Breast Neoplasm

Summary: in this study, positron emission tomography (pet/ct) imaging will be used to evaluate sigma-2 (σ2) receptor activity in sites of primary breast cancer using the investigational radiotracer \[18f\]iso-1.

this study will evaluate the feasibility of using \[18f\]iso-1 pet/ct to image sigma-2 receptor binding in primary breast tumors and continue to evaluate the safety of the tracer in this patient population. \[18f\]iso-1 uptake measures will be correlated with qualitative immunohistochemical staining for cell proliferation (ki67). this is an observational study in that \[18f\]iso-1 pet/ct will not be used to direct treatment decisions.

Eligibility criteria:
inclusion criteria: 1. adult patients, at least 18 years of age 2. known or suspected breast cancer with at least one breast lesion that is 1 cm or greater in size by standard imaging (e.g. mammography, ultrasound or breast mri) 3. participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures exclusion criteria: 1. females who are pregnant at the time of screening will not be eligible for this study, urine or serum pregnancy test will be performed in women of child-bearing potential at the time of screening. 2. inability to tolerate imaging procedure in the opinion of an investigator or treating physician 3. serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study. 4. unwilling or unable to provide informed consent.